PIOGLITAZON ACTAVIS

15MG TBL NOB 28 KAL

Maximum ex-factory price/Ex-factory price ? 236,88 CZK
Legal basis of maximum ex-factory price/ex-factory price ? Maximum ex-factory price announced under the law.

Informace o základní úhradě

Core reimbursement from health insurance ? 135,54 CZK
Maximum reimbursement from health insurance ? 201,60 CZK
Legal basis of reimbursement from health insurance ? Reimbursement set by the law.
Indication restriction of reimbursement ? Pioglitazon je hrazen pro léčbu diabetes mellitus 2. typu u pacientů s klinicky zřetelně manifestovanou inzulinovou rezistencí. Léčba je ukončena, pokud nedojde do 6 měsíců k prokazatelnému zlepšení kompenzace diabetu léčbou pioglitazonem (pokles hodnoty HbA1c nejméně o 10 %). V kombinaci s inzulinem nebo inzulinem a metforminem je pioglitazon hrazen při preskripci lékařem s odborností v oboru diabetologie (DIA).
Prescribing doctor's specialisation ?
Reporting limit ?
Rough price for the final consumer ? 353,16 CZK
Rough payment for the final consumer (for 1 prescribed package dispensed) ? 151.56 CZK
Eligible extra payment ? 46,83 CZK
Eligible extra payment for individuals aged 65 and older ? 46,83 CZK
Medicinal products reimbursed from health insurance contain the amount of the maximum manufacturer´s price or the producer´s notified price for products which are not subjected to the regulation of the maximum manufacturer´s price, the amount of reimbursement from health insurance and the estimated price for the end consumer (pharmacy price).

Back to list